Full Press Release Details
Immutep Presents New and Significant Data from the AIPAC Study.
IMMP
Immutep Presents New and Significant Data from the AIPAC Study
Key Takeaway: Immutep Presents New and Significant Data from the AIPAC Study
Price reaction · baseline $2.4 (2022-05-03 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close
+7.9%
day 1
+1.7%
day 3
-8.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)